Successful Treatment of Lung Calciphylaxis With Sodium Thiosulfate in a Patient With Sickle Cell Disease

A Case Report

Romain Arrestier, MD, Caroline Dudreuilh, MD, Philippe Remy, MD, Ghada Boulahia, MD, Bouteina Bentara, MD, Claire Leibler, MD, Amir Adedjouma, MD, Tomek Kofman, MD, Marie Matignon, MD, PhD, Dil Sahali, MD, PhD, Roger Dufresne, MD, Jean-François Deux, MD, PhD, Charlotte Colin, MD, Philippe Grimbert, MD, PhD, Philippe Lang, MD, PhD, Pablo Bartolucci, MD, PhD, Bernard Maitre, MD, PhD, Jeanne Tran Van Nieuw, MD, PhD, and Vincent Audard, MD, PhD

Abstract: Calciphylaxis is a small vessel vasculopathy, characterized by medial wall calcification that develops in a few patients with chronic renal failure. The prognosis of skin calciphylaxis has improved considerably since the introduction of sodium thiosulfate (STS), but it remains unclear whether this therapy is effective against organ lesions related to calciphylaxis. Pulmonary calciphylaxis is a usually fatal medical condition that may occur in association with skin involvement in patients with end-stage renal disease.

We report here the case of a 49-year-old woman homozygous sickle cell disease patient on chronic hemodialysis with biopsy-proven systemic calciphylaxis involving the lungs and skin. On admission, ulcerative skin lesions on the lower limbs and bilateral pulmonary infiltrates on chest computerized tomography scan were the main clinical and radiological findings. Skin and bronchial biopsies demonstrated calciphylaxis lesions. The intravenous administration of STS in association with cinacalcet for 8 consecutive months led to a clear improvement in skin lesions and thoracic lesions on chest computerized tomography scan.

This case suggests for the first time that organ lesions related to calciphylaxis, and particularly lung injury, are potentially reversible. This improvement probably resulted from the combination of 3 interventions (more frequent dialysis, cinacalcet, and STS), rather than the administration of STS alone.

INTRODUCTION

Calciphylaxis, or calcific uremic arteriolopathy, is a rare, life-threatening medical condition related to a mineral and bone disorder that occurs mostly in patients with end-stage renal disease (ESRD) on dialysis. Its prevalence among hemodialysis patients has been reported to be up to 4% and its mortality rate is 40% to 80% after diagnosis.3–5 Painful ischemic purpura lesions and necrotic ulceration, generally affecting the lower limbs, are the hallmark cutaneous manifestations of calciphylaxis.2 The pathophysiological processes involved in the development of calciphylaxis remain uncertain but some risk factors have been identified, including Caucasian ethnicity, being female, impaired calcium and phosphorus metabolism, warfarin treatment, diabetes mellitus, obesity, hypoalbuminemia, and prolonged dialysis.6 The main histological features of the skin are medial calcification with local inflammation and intimal hypertrophy leading to vessel obstruction and cutaneous necrosis.4,7 Although skin lesions are the main clinical manifestations of calciphylaxis, other organs, including skeletal muscle, the lungs, brain, eyes, pancreas, and digestive tract, may also develop calciphylaxis lesions.2 Pulmonary calciphylaxis (PC) is rare and probably underdiagnosed because it can occur in the absence of clinical manifestations, but is usually fatal when associated with pulmonary clinical symptoms of the disease.8 Promising treatments that may stabilize the disease or improve its outcome, such as sodium thiosulfate (STS), have recently emerged as the gold standard therapy for calciphylaxis.9 Nevertheless, the beneficial effect of this therapeutic approach remains to be determined in patients with PC. We report here the case of a 49-year-old female sickle cell disease (SCD) patient on hemodialysis, who was successfully treated by intravenous STS in association with cinacalcet for systemic calciphylaxis with skin and lung lesions.

CLINICAL REPORT

In July 2013, a 49-year-old woman from Caribbean origin with ESRD treated by chronic intermittent hemodialysis...
(initiated in 2008) was referred to our nephrology department for clinical evaluation before potential renal transplantation. Her relevant medical history included homozygous SCD with multiple vaso-occlusive crises and many episodes of acute chest syndrome. Chronic organ dysfunction related to SCD was observed, in the form of chronic kidney disease, post-transfusion iron overload and dilated cardiomyopathy with significant mitral insufficiency (stage 3). The patient had been on warfarin treatment since 2012 for paroxysmal atrial fibrillation. She was also on sevelamer, hydroxyurea, folic acid supplements, amiodarone, and ramipril, but was not taking calcium salt and vitamin D supplements. The patient received iron-chelating treatment (deferasirox) because of iron overload diagnosis. Physical examination on admission revealed multiple ulcerative skin lesions of 3 months’ duration on the lower limbs, but no definitive diagnosis was possible on the basis of the initial skin biopsy. Laboratory tests yielded the following results: serum calcium concentration = 2.54 mmol/L, serum phosphate concentration = 1.9 mmol/L, PTH concentration = 330 ng/L (normal range: 10–65 ng/L), albumin concentration = 33 g/L (normal range: 35–45 g/L) and CRP concentration = 27 mg/L. Hemoglobin level was 7.5 g/dL, and the patient had a white blood cell count of 4.2 × 10^9/L (with a differential count of 2.6 × 10^9 neutrophils/L and 1.4 × 10^9 lymphocytes/L) and 291 × 10^9 platelets/L. On admission, she had 4.2% HbF, 68.4% HbS, and 16.7% HbA1. She underwent transfusion with red blood cells every 6 weeks, approximately, to keep hemoglobin levels stable. The patient tested negative for antineutrophil cytoplasmic, antinuclear, and anti-DNA antibodies. Serum complement levels were within the normal range. Bone x-ray showed diffuse small artery and cutaneous calcifications without osteolytic lesions on the lower legs. A definitive diagnosis of calciphylaxis was made on the basis of a second skin biopsy showing subcutaneous small to medium-sized blood vessel calcifications associated with microthrombosis and intimal fibroplasia of panicular arterioles. Chest x-ray showed bilateral pulmonary infiltrates consisting of micronodules, predominantly at the top of the lungs (Figure 1). A thoracic CT scan revealed tree-bud opacities of the upper lobes associated with confluent alveolar opacities without intrathoracic adenopathy (Figure 2A). An accessory salivary gland biopsy provided no evidence of granuloma but was classified as Chisholm grade 1 (on a scale of 0–4). There were no clinical symptoms suggestive of lung involvement, but the results of the thoracic CT scan led us to perform bronchoalveolar lavage, which revealed a hypercellular fluid (with >9 × 10^5 cells/mL) with a normal differential count (97% macrophages). Direct examination and cultures identified no viral, bacterial or parasitic pathogens. Bronchial biopsies showed a modified epithelium with the calcification of elastic fibers and calcium deposits in alveolar septal capillary walls, with moderate inflammatory infiltration, consistent with the diagnosis of PC (Figure 3). Pulmonary function tests showed that total lung capacity had decreased to 70% whereas...
pulmonary resistance had increased to 195%, suggesting restrictive pulmonary disease.

Systemic calciphylaxis was first treated by replacing warfarin with aspirin, increasing the frequency of dialysis (to 5 sessions per week) with a low calcium dialysate and providing nutritional support. Intravenous STS therapy was then initiated at a dose of 10 g 5 times per week for 4 months, progressively increasing to 12.5 g 5 times per week for an additional 4 months. In parallel, cinacalcet therapy (initial dose 60 mg/day) was initiated to limit hyperparathyroidism. Skin lesions did not require surgical wound debridement. Serum phosphate and calcium concentrations during treatment are summarized in Table 1. Six months after treatment initiation, the patient returned to the Caribbean. One year later, the patient was admitted to our department for clinical evaluation. A thoracic CT scan (Figure 2B) showed a substantial improvement in pulmonary lesions concomitant with a significant regression of skin lesions. This improvement in clinical and radiological calciphylaxis lesions was not associated with an improvement in pulmonary function test. Unfortunately, the patient died 3 months later, during hemodialysis, from a cardiac arrest of unknown cause.

The authors did not obtain written consent of the patient because the patient died before we started to work on her case.

### DISCUSSION

Skin manifestations are the predominant clinical lesions observed in patients with calciphylaxis. Our patient displayed cutaneous features of calciphylaxis, which were assessed by skin histology. Pulmonary calcifications on CT scan associated with calcium deposits in bronchial mucosa were highly suggestive of specific pulmonary involvement. The main calciphylaxis triggers identified in this case were warfarin and dialysis over a period of several years. In accordance with the advice of the cardiologist, we therefore decided to replace warfarin with aspirin, to limit the risk of further damage on warfarin treatment. Another factor potentially promoting calciphylaxis in this case was SCD, which is a well-known cause of endothelial dysfunction and leukocyte and platelet activation leading to chronic inflammation and hypercoagulation. Acute chest syndrome is a major cause of lung ischemia reperfusion injury and may also promote PC. Nevertheless, the few studies describing SCD patients with ESRD treated by dialysis did not focus on this specific complication. In our patient, the severity of calciphylaxis, including PC associated with skin lesions, led us to propose a multi-interventional curative approach involving the administration of both cinacalcet and STS. Cinacalcet has already been proposed as a promising treatment for calciphylaxis. Further prospective controlled randomized studies are required to demonstrate a clear curative effect of STS, but this treatment has recently emerged as the cornerstone of calciphylaxis treatment. The optimal duration, mean dose and frequency of administration of STS were recently described by Nigwekar et al in a study of 172 patients. The mechanisms of action of STS remain elusive, although this drug is thought to increase the solubility of calcium.
calcium phosphate through the formation of highly soluble calcium thiosulfate complexes and to have antioxidant and vasodilating properties. Pulmonary calciphylaxis is a rare complication in patients on dialysis and it is unclear whether STS is an effective treatment for this potentially fatal complication. Previous case reports of PC in patients on dialysis not receiving STS highlighted the potentially life-threatening nature of this medical condition, which frequently causes chronic respiratory failure or death. Cadavid et al described 1 patient with metastatic calcification and skin lesions suggestive of calciphylaxis in whom parenchymal infiltration was not significantly improved by STS and cinacalcet treatment. Nevertheless, the diagnosis of calciphylaxis in this patient was suspected on clinical grounds but not confirmed by biopsy, and no information was provided about the follow-up period. In our patient, after 1 year of follow-up, treatment with STS (administered for 8 months) in association with cinacalcet and an increase in dialysis frequency led to a significant improvement of parenchymal lung lesions, suggesting that chest injury is reversible with this therapeutic approach. This improvement probably resulted from the combination of 3 interventions (more frequent dialysis, cinacalcet, and STS), rather than the administration of STS alone. Nevertheless, our patient died for unknown reasons, possibly related to a thrombotic event due to warfarin withdrawal.

In conclusion, the findings for this case suggest that systemic organ damage, affecting the lungs in particular, should be systematically sought in patients with isolated apparent skin calciphylaxis. Sickle cell disease may be an additional risk factor for calciphylaxis, but this remains to be definitively demonstrated. Further studies are required to confirm the value of STS therapy for patients with PC, but this case strongly suggests that lung injury can be reversed by STS.

REFERENCES

1. Brandenburg VM, Kramann R, Specht P, et al. Calciphylaxis in CKD and beyond. Nephrol Dial Transplant. 2012;27:1314–1318.
2. Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66:133–146.
3. Hayashi M, Takamatsu I, Kanno Y, et al., Japanese Calciphylaxis Study Group. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27:1580–1584.
4. Rogers NM, Coates PT. Calcific uremic arteriolopathy: an update. Curr Opin Nephrol Hypertens. 2008;17:629–634.
5. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int. 2002;61:2210–2217.
6. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches. Oxid Med Cell Longev. 2010;3:109–121.
7. Weenig RH. Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008;58:458–471.
8. Belém LC, Zanetti G, Souza AS Jr et al. Metastatic pulmonary calcification: state-of-the-art review focused on imaging findings. Respir Med. 2014;108:668–676.
9. Zitt E, König M, Vychytil A, et al. Use of sodium thiosulfate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant. 2013;28:1232–1240.
10. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Semin Thromb Hemost. 2011;37:226–236.
11. Maigne G, Ferlicot S, Galacteros F, et al. Glomerular lesions in patients with sickle cell disease. Medicine (Baltimore). 2010;89:18–27.
12. McClellan AC, Luthi JC, Lynch JR, et al. High one year mortality in adults with sickle cell disease and end-stage renal disease. Br J Haematol. 2012;159:360–367.
13. Salmofoer H, Franzen M, Hitzel W, et al. Multimodal treatment of calciphylaxis with sodium-thiosulphate, cinacalcet and sevelamer including long-term data. Kidney Blood Press Res. 2013;37:346–359.
14. Nigwekar SU, Brunelli SM, Meade D, et al. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8:1162–1170.
15. Matsu T, Tsukamoto Y, Tamura M, et al. Acute respiratory failure due to “pulmonary calciphylaxis” in a maintenance haemodialysis patient. Nephron. 2001;87:75–79.
16. Beyzaei A, Francis J, Knight H, et al. Metabolic lung disease: diffuse metastatic pulmonary calcifications with progression to calciphylaxis in end-stage renal disease. Adv Perit Dial. 2007;21:112–117.
17. Li YJ, Tian YC, Chen YC, et al. Fulminant pulmonary calciphylaxis and metastatic calcification causing acute respiratory failure in a uremic patient. Am J Kidney Dis. 2006;47:47–53.
18. Madhusudhan KS, Shad PS, Sharma S, et al. Metastatic pulmonary calcification in chronic renal failure. Int Urol Nephrol. 2012;44:1285–1287.
19. Cadavid JC, DiVietro ML, Torres EA, et al. Warfarin-induced pulmonary metastatic calcification and calciphylaxis in a patient with end-stage renal disease. Chest. 2011;139:1503–1506.